Mochi Health Review 2026: The GLP-1 Platform Built Around Obesity Medicine

What Is Mochi Health?

Founded in 2022 by physician Myra Ahmad, Mochi Health is a San Francisco-based telehealth platform that bills itself as the nation's largest GLP-1 program by enrollment, with more than 500,000 patients served across all 50 states. Unlike the generic urgent-care model common in weight-loss telehealth, Mochi built its clinical network around obesity medicine specialists — physicians who hold board certification from the American Board of Obesity Medicine (ABOM), a credential that requires dedicated training in the metabolic science of weight regulation. That's a meaningful differentiator in a market crowded with nurse practitioners and general practitioners prescribing GLP-1s as a side offering.

The platform covers weight loss, hormones, skincare, and hair loss, but GLP-1 medications are its marquee product. Members interact primarily through asynchronous messaging and scheduled video visits, with care decisions made by the physician of record and carried out through a network of partner compounding pharmacies that ship directly to the patient's door.

How Mochi Health Works

Getting started takes about 10 minutes. You fill out a health history questionnaire, answer questions about your weight-loss goals, and upload any recent labs you have on hand. Mochi then matches you with an ABOM-certified physician or nurse practitioner who reviews your intake and, if appropriate, issues a prescription during a video consultation. The entire process — intake to first shipment — typically takes three to five business days.

• Complete online intake form (weight, medical history, goals)
• Video or asynchronous consultation with an obesity medicine provider
• Prescription sent to Mochi's compounding pharmacy network
• Medication ships directly to your door with free shipping
• Ongoing check-ins through the patient portal; dose adjustments as needed

Labs are not included in the standard plan and are not required to start. Mochi recommends that patients order baseline bloodwork through their own primary care provider or a third-party lab service. Insurance is not accepted for either the membership fee or the medication cost.

Medications: Four Formats of Semaglutide and More

Mochi's medication menu is one of the broadest in telehealth. The headline offering is compounded semaglutide in four distinct formats: subcutaneous injection (the standard weekly shot), oral tablet, oral drops, and microdose. The oral and microdose options appeal to patients who are needle-averse or want a more gradual titration curve. Mochi also offers compounded tirzepatide injection and a roster of branded medications including Ozempic, Wegovy, Mounjaro, and Zepbound for patients who prefer or require the FDA-approved versions.

For women in perimenopause or menopause, the breadth of format options matters. Hormonal shifts during this transition frequently drive insulin resistance, appetite dysregulation, and rapid visceral fat accumulation — the exact mechanisms that GLP-1 receptor agonists target. Having the choice between an injection and an oral formulation can make the difference between a woman who stays on therapy long enough to see results and one who stops after the first injection anxiety.

• Compounded semaglutide injection — weekly subcutaneous, dose range 0.22 mg to 2.67 mg
• Compounded semaglutide oral tablet — for needle-averse patients
• Compounded semaglutide oral drops — sublingual liquid option
• Compounded semaglutide microdose — slower titration for sensitive patients
• Compounded tirzepatide injection — dual GIP/GLP-1 agonist, weekly shot
• Branded Ozempic, Wegovy, Mounjaro, Zepbound (available; pricing separate)

Pricing: What You Actually Pay

Mochi uses a two-part pricing model: a flat membership fee plus a flat medication fee. The membership is $79 per month and covers provider access, messaging, and care coordination. Compounded semaglutide (any format) is $99 per month. Compounded tirzepatide is $199 per month. Critically, neither medication price increases as your dose escalates — a significant advantage over platforms that charge more as you move to higher maintenance doses.

That puts all-in costs at $178 per month for semaglutide or $278 per month for tirzepatide, including shipping. For context, branded Wegovy without insurance routinely lists above $1,300 per month, and out-of-pocket tirzepatide (Zepbound) runs $550–$650 per month at pharmacy retail. Mochi's compounded pricing is among the most transparent in telehealth — there are no hidden lab fees or mandatory add-ons in the standard plan.

Annual cost estimate: $2,136 per year for semaglutide ($178 x 12) or $3,336 per year for tirzepatide ($278 x 12). Mochi periodically offers discounts on first-month membership and on 3- and 12-month medication commitments.

Reputation: What Patients and Regulators Say

Mochi holds a 4.4 out of 5 rating on Trustpilot across more than 15,000 reviews as of June 2026 — a strong score for a telehealth platform this size. Positive reviews consistently highlight the quality and accessibility of the physician team, the flat-dose pricing model, and the variety of medication formats. Negative reviews cluster around billing confusion (the $79 membership fee on top of medication costs surprises some patients), slow provider response times during high-demand periods, and shipping delays that followed the Aequita pharmacy closure in early 2025.

The Aequita situation is worth understanding in detail. Aequita was Mochi's primary compounding pharmacy partner until Washington State issued a Notice of Immediate Jeopardy in March 2025, shutting it down for sterile compounding violations that included unlicensed workers handling medications. As of mid-2026, Mochi has diversified to 33 or more compounding pharmacy partners and shifted Washington-state fulfillment to Key Compounding in Federal Way, WA. However, investigative reports in early 2026 flagged ongoing quality concerns at another Mochi-affiliated compounding facility, suggesting the platform's pharmacy vetting processes remain a work in progress.

On the regulatory front, the FDA proposed on April 30, 2026, to remove semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list. The public comment period closes June 29, 2026, and no final rule has been issued as of the date of this review. Patients considering Mochi should factor this regulatory risk into their long-term planning.

Who Mochi Health Is Best For

Mochi Health is well-suited for patients who want expert-level obesity medicine oversight without the cost of an in-person bariatric practice. The ABOM physician network is a genuine clinical differentiator — these providers understand the metabolic complexity behind weight gain, including the role of hormonal changes during perimenopause and menopause. Women in their 40s and 50s who are experiencing the weight-redistribution and appetite shifts that accompany the menopause transition will find providers here who speak that language, rather than attributing all symptoms to willpower.

• Adults with a BMI of 27+ who have not responded to lifestyle changes alone
• Perimenopausal and menopausal women managing metabolic changes alongside GLP-1 therapy
• Patients who want compounded GLP-1s at a flat dose-insensitive price
• Needle-averse patients who prefer oral or drop formats of semaglutide
• People in rural or underserved areas who lack access to in-person obesity medicine
• Patients comfortable managing their own labs outside the platform

Mochi is a weaker fit for patients who want bundled labs, who need insurance billing, or who prioritize pharmacy supply-chain certainty above all else given the ongoing post-Aequita pharmacy expansion.

Verdict

Mochi Health earns its reputation as the heavyweight in GLP-1 telehealth. The ABOM physician network, four-format semaglutide menu, and flat-rate pricing that doesn't penalize you for needing a higher dose are genuine advantages that most competitors cannot match. For perimenopausal and menopausal women in particular, access to metabolically informed physicians who understand hormonal weight gain is worth the $79 monthly membership.

The pharmacy track record is the credible knock against the platform. The Aequita closure was a serious patient safety event, and subsequent reporting suggests compounding oversight is still being tightened. The FDA's proposed 503B exclusion also introduces real medium-term supply risk for anyone building a treatment plan around compounded GLP-1s. Go in with eyes open: Mochi is clinically excellent and competitively priced, but you should ask your provider which pharmacy will be filling your script and verify it holds current state licensure.